Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Attention-Deficit/Hyperactivity Disorder | Treatment Algorithms: Claims Data Analysis | Adult | US | 2023
Attention-deficit / hyperactivity disorder (ADHD) is one of the most common childhood mental health disorders that can continue into adulthood. This condition entails several recurring problems,…
Bispecific Therapies – Special Topics – Special Topics: Bispecific Therapies (G7 and China)
Bispecific therapies represent a class of drug with two binding sites directed at two different antigens or epitopes. This dual action makes bispecific therapies a promising approach to improve…
Cell Therapies in Oncology: Clinical Pipeline Analysis & Development Trends | G7 and China | 2021
Cell therapy uses viable healthy cells to replace, expand, and/or enhance a population of cells in order to achieve a therapeutic effect against a disease. The cell therapy field is rapidly…
Attention-Deficit/Hyperactivity Disorder | Treatment Algorithms: Claims Data Analysis | Adult | US | 2021
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood disorder that can persist into adulthood, although diagnosis and treatment initiation can occur at any age. Data suggest that…
Attention-Deficit/Hyperactivity Disorder | Treatment Algorithms: Claims Data Analysis | Adult | US | 2020
Attention-deficit / hyperactivity disorder (ADHD) is a common childhood disorder that can persist into adulthood, although diagnosis and treatment initiation can occur at any age. Diagnosis and…
Rare Diseases and Orphan Drugs – Access & Reimbursement – Rare Diseases and Orphan Drugs – Top Five European Markets
MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of rare diseases treatment, and ongoing industry focus are key drivers of growth in…
Biosimilars Advisory Service: Acceptance of Biosimilars Across Physician Specialties | Biosimilars Advisory Service | US/EU | 2014
The fledgling biosimilars industry is full of uncertainties and nuances that differ by country, therapeutic specialty, and molecule. Securing a positive return on lengthy biosimilar development…